ANI PHARMACEUTICALS, INC Interest Rate Derivative Assets, at Fair Value
ANI PHARMACEUTICALS, INC (ANIP) had Interest Rate Derivative Assets, at Fair Value of $1.12 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes
us-gaap:InterestRateDerivativeAssetsAtFairValue · last filed 2026-08-07
- 2026-06-30: Interest Rate Derivative Assets, at Fair Value $1.12M.
- 2026-03-31: Interest Rate Derivative Assets, at Fair Value $1.51M.
- 2025-12-31: Interest Rate Derivative Assets, at Fair Value $1.65M.
- 2025-09-30: Interest Rate Derivative Assets, at Fair Value $2.23M.
| Period end | Interest Rate Derivative Assets, at Fair Value |
|---|---|
| 2026-06-30 | $1.12M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $1.51M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $1.65M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $2.23M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $2.81M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $3.61M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $4.90M 10-K · filed 2026-02-27 |
| 2024-09-30 | $3.56M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $7.37M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $7.65M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $6.24M 10-K · filed 2025-02-28 |
| 2023-09-30 | $10.01M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $9.17M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $6.86M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $8.76M 10-K · filed 2024-02-29 |
| 2022-09-30 | $9.37M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $3.64M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $431.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |